LEO Pharma Presents Real-World Evidence for Dermatology Portfolio at AAD 2026
Key Insights
LEO Pharma presented 17 scientific abstracts at the 2026 American Academy of Dermatology Annual Meeting, showcasing real-world evidence for its dermatology treatments.
The presentations covered three key therapeutic areas: atopic dermatitis (search) with ADBRY (tralokinumab), generalized pustular psoriasis (search) with SPEVIGO (spesolimab), and chronic hand eczema (search) with ANZUPGO (delgocitinib).
Data from the international TRACE study demonstrated sustained effectiveness of tralokinumab over 12 months in patients with moderate-to-severe atopic dermatitis (search).
LEO Pharma showcased comprehensive real-world evidence across its dermatology portfolio at the 2026 American Academy of Dermatology Annual Meeting in Denver, presenting 17 scientific abstracts that highlight long-term outcomes and patient experiences with three key treatments.
ADBRY Demonstrates Sustained Real-World Effectiveness
The company presented final data from the international TRACE study, a prospective, non-interventional study examining 12-month outcomes with ADBRY (tralokinumab) in patients with moderate-to-severe atopic dermatitis (search). The study included 495 adult patients with atopic dermatitis and hand and foot involvement, demonstrating real-world effectiveness of the IL-13 (search) inhibitor.
ADBRY is a high-affinity fully human monoclonal antibody that specifically binds to the IL-13 (search) cytokine, inhibiting interaction with IL-13 receptor α1 and α2 subunits. The treatment is approved for moderate-to-severe atopic dermatitis (search) in patients 12 years and older across multiple regions including the United States, European Union, Canada, and several other countries.
Additional TRACE study data showed effectiveness in patients with skin of color, addressing an important population often underrepresented in clinical trials. The study also demonstrated minimal disease activity achievement with 12 months of tralokinumab treatment.
SPEVIGO Shows Long-Term Prevention of GPP Flares
LEO Pharma presented long-term efficacy data for SPEVIGO (spesolimab) from the EFFISAYIL program, showing sustained prevention of flares in patients with generalized pustular psoriasis (search) over three years of treatment. The data comes from the 5-year, open-label EFFISAYIL ON extension study.
SPEVIGO is a humanized, selective antibody that blocks activation of the IL-36R (search) signaling pathway, which is involved in the pathogenesis of generalized pustular psoriasis (search). It represents the first targeted therapy for GPP treatment and has been evaluated in the largest clinical program specifically designed for GPP patients.
Generalized pustular psoriasis (search) is a chronic, neutrophilic inflammatory disease distinct from plaque psoriasis, with mortality rates ranging from 2% to 16% due to severe complications including multisystem organ failure and sepsis. The IL-36 pathway serves as a key driver of GPP pathophysiology.
ANZUPGO Data Reinforces CHE Treatment Benefits
The company presented outcomes data for ANZUPGO (delgocitinib) cream, the first and only FDA-approved topical pan-JAK (search) inhibitor for chronic hand eczema (search). Data from the phase 3 open-label extension DELTA 3 trial showed sustained health-related quality of life improvements with delgocitinib 20 mg/g cream.
Additional presentations included outcomes over 16 weeks by prior systemic therapy exposure and safety profile data from the DELTA TEEN phase 3 trial in adolescents with moderate to severe chronic hand eczema (search).
Chronic hand eczema (search) affects approximately one in ten adults in the United States and is characterized by substantial impairment in daily activities, with average activity impairment exceeding 40%. The condition significantly impacts careers and earning potential for affected individuals.
Patient Experience and Quality of Life Focus
Several presentations emphasized patient-reported outcomes and quality of life measures. The CHECK study in the United States provided insights into patient-perceived factors associated with chronic hand eczema (search) and health-related quality of life impacts in affected individuals.
LEO Pharma also presented data on pyoderma gangrenosum (search), including prevalence of comorbidities, mortality and adverse outcomes, and patient perspectives on disease signs, symptoms and impacts through qualitative research.
The comprehensive data presentation underscores LEO Pharma's commitment to generating real-world evidence across its dermatology portfolio, with particular emphasis on long-term outcomes and patient experience measures that complement traditional clinical trial endpoints.